| Transmissible SARS-CoV-2 variants with resistance to clinical protease inhibitors SA Moghadasi, E Heilmann, AM Khalil, C Nnabuife, FL Kearns, C Ye, ... Science Advances 9 (13), eade8778, 2023 | 125 | 2023 |
| SARS-CoV-2 3CLpro mutations selected in a VSV-based system confer resistance to nirmatrelvir, ensitrelvir, and GC376 E Heilmann, F Costacurta, SA Moghadasi, C Ye, M Pavan, D Bassani, ... Science translational medicine 15 (678), eabq7360, 2022 | 97 | 2022 |
| HIV-1 Vif triggers cell cycle arrest by degrading cellular PPP2R5 phospho-regulators DJ Salamango, T Ikeda, SA Moghadasi, J Wang, JL McCann, ... Cell reports 29 (5), 1057-1065. e4, 2019 | 43 | 2019 |
| Evolution-guided structural and functional analyses of the HERC family reveal an ancient marine origin and determinants of antiviral activity E Paparisto, MW Woods, MD Coleman, SA Moghadasi, DS Kochar, ... Journal of virology 92 (13), 10.1128/jvi. 00528-18, 2018 | 35 | 2018 |
| Natural APOBEC3C variants can elicit differential HIV-1 restriction activity BD Anderson, T Ikeda, SA Moghadasi, AS Martin, WL Brown, RS Harris Retrovirology 15, 1-11, 2018 | 30 | 2018 |
| Gain-of-Signal Assays for Probing Inhibition of SARS-CoV-2 Mpro/3CLpro in Living Cells SA Moghadasi, MA Esler, Y Otsuka, JT Becker, SN Moraes, CB Anderson, ... MBio 13 (3), e00784-22, 2022 | 22 | 2022 |
| Rapid resistance profiling of SARS-CoV-2 protease inhibitors SA Moghadasi, RG Biswas, DA Harki, RS Harris npj Antimicrobials and Resistance 1 (1), 9, 2023 | 21 | 2023 |
| A VSV-based assay quantifies coronavirus Mpro/3CLpro/Nsp5 main protease activity and chemical inhibition DL Emmanuel Heilmann, Francesco Costacurta, Stephan Geley, Seyed Arad ... Communications Biology 5 (1), 2022 | 17 | 2022 |
| Evidence linking APOBEC3B genesis and evolution of innate immune antagonism by gamma-herpesvirus ribonucleotide reductases SN Moraes, JT Becker, SA Moghadasi, NM Shaban, AA Auerbach, ... elife 11, e83893, 2022 | 11 | 2022 |
| DNA-encoded chemical libraries yield non-covalent and non-peptidic SARS-CoV-2 main protease inhibitors R Jimmidi, S Chamakuri, S Lu, MN Ucisik, PJ Chen, KM Bohren, ... Communications Chemistry 6 (1), 164, 2023 | 9 | 2023 |
| SARS-CoV-2 3CL (pro) mutations selected in a VSV-based system confer resistance to nirmatrelvir, ensitrelvir, and GC376. Sci. Transl. Med. 15, eabq7360 E Heilmann, F Costacurta, SA Moghadasi, C Ye, M Pavan, D Bassani, ... | 8 | 2022 |
| Transmissible SARS-CoV-2 variants with resistance to clinical protease inhibitors. bio Rxiv: 2022.08. 07.503099 SA Moghadasi, E Heilmann, AM Khalil, C Nnabuife, FL Kearns, C Ye, ... There is no corresponding record for this reference, 2022 | 8 | 2022 |
| Ancestral APOBEC3B nuclear localization is maintained in humans and apes and altered in most other Old World primate species AA Auerbach, JT Becker, SN Moraes, SA Moghadasi, JM Duda, ... Msphere 7 (6), e00451-22, 2022 | 5 | 2022 |
| Transmissible SARS-CoV-2 variants with resistance to clinical protease inhibitors. bioRxiv (2022) SA Moghadasi, E Heilmann, A Khalil, C Nnabuife, FL Kearns, C Ye, ... Google Scholar, 0 | 5 | |
| Mitochondrial double-stranded RNA triggers induction of the antiviral DNA deaminase APOBEC3A and nuclear DNA damage C Wick, SA Moghadasi, JT Becker, E Fanunza, S Oh, E Bournique, ... Journal of Biological Chemistry 299 (9), 2023 | 4 | 2023 |
| A comprehensive study of SARS-CoV-2 main protease (Mpro) inhibitor-resistant mutants selected in a VSV-based system F Costacurta, A Dodaro, D Bante, H Schöppe, JY Peng, B Sprenger, X He, ... PLoS Pathogens 20 (9), e1012522, 2024 | 3 | 2024 |
| A compact stem-loop DNA aptamer targets a uracil-binding pocket in the SARS-CoV-2 nucleocapsid RNA-binding domain MA Esler, CA Belica, JA Rollie, WL Brown, SA Moghadasi, K Shi, ... Nucleic acids research 52 (21), 13138-13151, 2024 | 2 | 2024 |
| Cellular Assays for Dynamic Quantification of Deubiquitinase Activity and Inhibition SA Moghadasi, SN Moraes, RS Harris Journal of Molecular Biology 435 (23), 168316, 2023 | 2 | 2023 |
| Highly specific SARS-CoV-2 main protease (Mpro) mutations against the clinical antiviral ensitrelvir selected in a safe, VSV-based system S Rauch, F Costacurta, H Schöppe, JY Peng, D Bante, EE Erisoez, ... Antiviral Research 231, 105969, 2024 | | 2024 |
| SARS-CoV-2 Mpro inhibitor identification using a cellular gain-of-signal assay for high-throughput screening R Delgado, J Vishwakarma, SA Moghadasi, Y Otsuka, J Shumate, A Cuell, ... SLAS Discovery 29 (6), 100181, 2024 | | 2024 |
